Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo

Lee, Mi-Young; Jeong, Sang Young; Ha, Jihun; Kim, Mi‐Yeon; Jin, Hye Jin; Kwon, Sang Hoon; Chang, Jong Wook; Choi, Soo Jin; Oh, Wonil; Yang, Yoon Sun; Kim, Jae-Sung; Jeon, Hong Bae

doi:10.1016/j.bbrc.2014.03.051

Cited by 153 publications

(121 citation statements)

References 30 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…After repeated intravenous injection of hPBMSCs or MRC5 cells into these mice, immunological alterations including T cell proliferation and increased IFN-γ, TNF-α, and human IgG levels, were observed. In contrast, hUCB-MSCs injection did not elicit these responses[122]. Meanwhile, Zanotti et al reported that the use of encapsulated cells unequivocally demonstrates that MSCs do not require homing to specific organs or cellcell contacts to control inflammation and their immunosuppressive action is based on the release of soluble factors that may act systemically[123].…”

mentioning

confidence: 96%

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Zhao¹,

Ren

Han

2016

Journal of Cellular Immunotherapy

242

193

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) represent a heterogenous population of adult,fibroblast-like multi-potent cells. MSCs have drawn much attention during the last decade in the field of regenerative medicine, mainly due to their capacity to differentiate into specific cell types, abundant production of soluble growth factors and cytokines, and hematopoiesis supporting properties. In addition, MSCs can migrate to the sites of inflammation and hold potent of immunomodulatory and anti-inflammatory effects through cell and cell interactions between MSCs and lymphocytes or production of soluble factors. Therefore, the application of MSCs in many disease situations is full of possibilities for future clinical treatment. Phase III clinical trials have been run using

show abstract

mentioning

confidence: 96%

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Zhao¹,

Ren

Han

2016

Journal of Cellular Immunotherapy

242

193

View full text Add to dashboard Cite

show abstract

“…The human UCB-MSCs used in this study were donated by Medipost Co., Ltd. UCB-MSCs were separated as previously described [31,32] and maintained in Dulbecco's modified Eagle's medium-high-glucose (Hyclone) supplemented with 2 mM L-glutamine, 20 mM HEPES (pH 7.3), MEM nonessential amino-acid solution, penicillin/streptomycin (Cellgro), 1 mg/mL ascorbic acid (Sigma), 10% heatinactivated FBS (Hyclone), 5 ng/mL human EGF, 10 ng/mL basic fibroblast growth factor, and 50 mg/mL Long R3 insulin-like growth factor-1 (IGF1; Prospec) in a 37°C humidified atmosphere that contained 5% CO 2 . UCB-MSCs were allowed to expand for six passages and then transplanted to ensure multipotency.…”

Section: Culturing Ucb-mscsmentioning

confidence: 99%

Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway

Song

Lim

et al. 2015

Stem Cells and Development

Self Cite

View full text Add to dashboard Cite

Interstitial cystitis (IC) is a syndrome characterized by urinary urgency, frequency, pelvic pain, and nocturia in the absence of bacterial infection or identifiable pathology. IC is a devastating disease that certainly decreases quality of life. However, the causes of IC remain unknown and no effective treatments or cures have been developed. This study evaluated the therapeutic potency of using human umbilical cord-blood-derived mesenchymal stem cells (UCB-MSCs) to treat IC in a rat model and to investigate its responsible molecular mechanism. IC was induced in 10-week-old female Sprague-Dawley rats via the instillation of 0.1 M HCl or phosphate-buffered saline (PBS; sham). After 1 week, human UCB-MSC (IC + MSC) or PBS (IC) was directly injected into the submucosal layer of the bladder. A single injection of human UCB-MSCs significantly attenuated the irregular and decreased voiding interval in the IC group. Accordingly, denudation of the epithelium and increased inflammatory responses, mast cell infiltration, neurofilament production, and angiogenesis observed in the IC bladders were prevented in the IC + MSC group. The injected UCB-MSCs successfully engrafted to the stromal and epithelial tissues and activated Wnt signaling cascade. Interference with Wnt and epidermal growth factor receptor activity by small molecules abrogated the benefits of MSC therapy. This is the first report that provides an experimental evidence of the therapeutic effects and molecular mechanisms of MSC therapy to IC using an orthodox rat animal model. Our findings not only provide the basis for clinical trials of MSC therapy to IC but also advance our understanding of IC pathophysiology.

show abstract

“…The hUCB harvests were processed within 24 hours of collection. The hUCB was isolated by separating mononuclear cells (MNCs) with Ficoll-Hypaque solution (density = 1.077 g/cm 3 ; Sigma-Aldrich, St. Louis, MO, http://www.sigmaaldrich.com).…”

Section: Cell Culturementioning

confidence: 99%

“…Mesenchymal stem cells derived from human umbilical cord blood (hUCB-MSCs) are characterized by self-renewal [1], a potential for differentiation into multiple cell lineages [2], low immunogenicity [3], and paracrine functions [4][5][6], suggesting that they may be beneficial in allogeneic MSC-based therapy. However, enabling MSC-based therapy requires expanding MSCs in large-scale production via long-term in vitro cultivation.…”

Section: Introductionmentioning

confidence: 99%

Downregulation of Melanoma Cell Adhesion Molecule (MCAM/CD146) Accelerates Cellular Senescence in Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells

Jin

Kwon

Kim

et al. 2016

Stem Cells Translational Medicine

Self Cite

View full text Add to dashboard Cite

CD146 expression is gradually decreased during the long‐term expansion of human umbilical cord blood‐derived mesenchymal stem cells (hUCB‐MSCs) in culture, and enforced CD146 downregulation accelerated senescence in hUCB‐MSCs, which affected their multilineage differentiation potential, growth, and stemness. These data indicate a possible role for CD146 in inhibiting senescence in hUCB‐MSCs, which may occur via the regulation of Bmi‐1, Id1, and Twist1 expression. CD146 may be a novel marker for predicting senescence in hUCB‐MSCs, and it could be valuable in quality‐control assessments and for improving the therapeutic potential of hUCB‐MSC‐based therapy.

show abstract

Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo

Cited by 153 publications

References 30 publications

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway

Downregulation of Melanoma Cell Adhesion Molecule (MCAM/CD146) Accelerates Cellular Senescence in Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells

Contact Info

Product

Resources

About